Cullinan Therapeutics, Inc. (CGEM)
| Market Cap | 992.55M +104.6% |
| Revenue (ttm) | n/a |
| Net Income | -221.04M |
| EPS | -3.72 |
| Shares Out | 61.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 771,611 |
| Open | 16.24 |
| Previous Close | 16.33 |
| Day's Range | 15.84 - 16.54 |
| 52-Week Range | 5.68 - 16.74 |
| Beta | -0.09 |
| Analysts | Strong Buy |
| Price Target | 31.14 (+92.82%) |
| Earnings Date | May 7, 2026 |
About CGEM
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CGEM stock is "Strong Buy." The 12-month stock price target is $31.14, which is an increase of 92.82% from the latest price.
News
Cullinan Therapeutics price target raised to $37 from $36 at Wedbush
Wedbush raised the firm’s price target on Cullinan Therapeutics (CGEM) to $37 from $36 and keeps an Outperform rating on the shares. The firm notes the company reported first quarter…
Cullinan Therapeutics reports Q1 EPS (75c), consensus (85c)
“T cell engagers have the potential to transform outcomes for people living with autoimmune diseases and cancer, and emerging clinical data underscore their promise as a compelling therapeutic modalit...
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
Initial clinical data in SLE and RA for CLN-978, a CD19 T cell engager, to be presented at the EULAR 2026 Congress in June; multi-dose regimen data in RA expected in Q3 2026 Zipalertinib NDA for rela...
Cullinan jumps after UCB acquires Candid Therapeutics
Shares of Cullinan Therapeutics (CGEM) are moving higher after UCB (UCBJF) announced an agreement to acquire privately held Candid Therapeutics. Cizutamig, Candid’s lead investigational asset, is “pos...
Cullinan Therapeutics price target raised to $30 from $27 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Cullinan Therapeutics (CGEM) to $30 from $27 and keeps a Buy rating on the shares after the FDA accepted…
Cullinan Therapeutics announces U.S. FDA accepted NDA for zipalertinib
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics (CGEM) announced that the U.S. Food and Drug Administration, FDA, has accepted a New Drug Application, NDA, for zipalertinib for the tre...
U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and...
Clear Street says Gilead-Ouro deal highlights upside for Cullinan’s velinotamig
Clear Street says that Gilead’s (GILD) up to $2.2B acquisition of Ouro Medicines’ sole asset OM336 underscores the potential of Cullinan Therapeutics’ (CGEM) velinotamig. This M&A serves as external v...
Cullinan Therapeutics price target raised to $36 from $34 at Wedbush
Wedbush raised the firm’s price target on Cullinan Therapeutics (CGEM) to $36 from $34 and keeps an Outperform rating on the shares. The firm notes the company reported Q4 financials…
Cullinan Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Major milestones are expected in 2026 for two T-cell engager programs targeting autoimmune diseases and AML, with key data readouts and regulatory progress anticipated throughout the year. Enhanced trial enrollment, strong early efficacy, and a robust cash position support continued advancement.
Cullinan Therapeutics reports Q4 EPS (77c), consensus (84c)
“Cullinan Therapeutics (CGEM) is poised to deliver multiple value-driving catalysts across our programs throughout 2026. Strong enrollment momentum for CLN-978 positions us to deliver the first compan...
Cullinan Therapeutics sees cash runway into 2029
Cash, cash equivalents, short- and long-term investments, and interest receivable were $439.0 million as of December 31, 2025. Cullinan expects its cash resources to provide runway into 2029 under its...
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Initial clinical data for CLN-978 in SLE and RA confirmed for Q2 2026; repeat dosing data in RA confirmed for Q3 2026 Zipalertinib rolling NDA submission completed; enrollment of REZILIENT3 frontline ...
Cullinan Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Key milestones are expected in 2026, with pivotal data from CLN-978 in autoimmune diseases and CLN-049 in AML anticipated throughout 2024. Both programs target significant unmet needs, with a focus on safety, efficacy, and efficient development paths.
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, h...
Cullinan Therapeutics Transcript: Citi’s 2026 Virtual Oncology Leadership Summit
Multiple clinical catalysts are expected in 2026, including key data for CLN-978 in autoimmune diseases and CLN-049 in AML, with expansion into pivotal studies. Zipalertinib is advancing toward NDA submission and frontline study completion, supported by a strong financial position.
Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit
CAMBRIDGE, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, h...
Cullinan Therapeutics initiated with a Buy at Citi
Citi initiated coverage of Cullinan Therapeutics (CGEM) with a Buy rating and $33 price target The firm says the company is advancing a pipeline of T-cell engagers across autoimmune and…
Cullinan Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Multiple portfolio catalysts are expected in 2026, with key data readouts for T cell engagers in autoimmune diseases and AML. Strong clinical progress, robust financial runway, and strategic partnerships position the company for significant growth and value creation.
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026
CAMBRIDGE, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, h...
Cullinan Therapeutics initiated with a Buy at Guggenheim
Guggenheim last night initiated coverage of Cullinan Therapeutics (CGEM) with a Buy rating and $30 price target The firm sees a good entry point early into an “important year” of…
Cullinan Therapeutics initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Cullinan Therapeutics (CGEM) with a Buy rating and $30 price target
Cullinan Therapeutics price target raised to $27 from $26 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Cullinan Therapeutics (CGEM) to $27 from $26 and keeps a Buy rating on the shares after the company announced its 2026 milestones.
Cullinan Therapeutics price target raised to $30 from $28 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Cullinan Therapeutics (CGEM) to $30 from $28 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S.
Cullinan Therapeutics provides corporate update, anticipated 2026 milestones
Cullinan Therapeutics (CGEM) provided a corporate update and shared anticipated business highlights for 2026. Highlights; Data readouts planned for CLN-978 across all three autoimmune indications in 2...